Amyris Biotechnologies Inc., an Emeryville, Calif.-based synthetic biology company that developers renewable hydrocarbon biofuels, has filed for a $100 million IPO. It plans to trade under ticker symbol AMRS, with Goldman Sachs, J.P. Morgan and Morgan Stanley serving as co-lead underwriters.
The company reports $64 million in 2009 revenue, compared to $14 million in 2008.
Amyris has raised over $240 million in VC funding, from Kleiner Perkins (15.4% pre-IPO stake), Kohsla Ventures (15.4%), TPG Biotech (12.1%), Advanced Equities (6.7%), Temasek Holdings, DAG Ventures, Votorantim Novos Negocios, Grupo Cornélio Brennand, Naxos UK, The Westly Group and Stratus Group. www.amyrisbiotech.com